Form 4: BridgeBio Pharma COO Thomas Trimarchi Reports Tax-Related Stock Disposal

Thomas Trimarchi, President and COO of BridgeBio Pharma, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.

Summary

• On February 16, 2025, Thomas Trimarchi, the President and COO of BridgeBio Pharma, Inc. (BBIO), reported a transaction involving the disposal of 13,782 shares of common stock.
• The shares were withheld by the issuer to satisfy Mr. Trimarchi's tax obligations related to the vesting of 32,431 shares of common stock underlying his restricted stock units.
• The transaction was executed at a price of $34.9 per share.
• Following the transaction, Mr. Trimarchi beneficially owns 414,205 shares of BridgeBio Pharma, Inc.

Sentiment

Score: 5

Explanation: This is a neutral event related to tax obligations. It doesn't inherently indicate positive or negative sentiment towards the company.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard tax-related stock disposal, which is a common occurrence when restricted stock units vest.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a routine tax-related disposal of shares.

Key Dates

Keywords

Form 4, BridgeBio Pharma, BBIO, Thomas Trimarchi, Stock Disposal, Tax Obligations, Restricted Stock Units, Beneficial Ownership, President, COO